Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.
Amitkumar Mehta, MD, MBA, associate professor of medicine and director of the lymphoma and chimeric antigen receptor (CAR) T-cell therapy programs, University of Alabama at Birmingham, highlights the synergy between CAR T-cell therapy and bispecifics in oncology.
Mehta delved into the topic more during the panel discussion, "Which Comes First? Bispecifics, CAR T-Cell Therapy, and Cost Consideration in Sequencing," at the Patient-Centered Oncology Care® (PCOC) 2023 meeting.
Transcript
Can you highlight some of the major points from your panel on bispecifics and CAR T-cell therapy?
I don't see CAR T and bispecifics as competing with each other, so they both are, in a way, complementary. Both of them [are] amazing advances in the treatments of oncology, as a matter of fact, and obviously lymphoma and myeloma kind of lead that growth. Now, all the solid tumors are also looking at that technology of bispecific antibody as well as CAR T-cell therapy.
When I look at both the therapies—as a matter of fact, for any therapies—I ask 1 question: whether this therapy can be potentially curative. The way we will know is if we have a longer follow-up and what proportion of patients have not needed treatment after therapy. So that is a key question. The longest data that we have is on CAR T-cell therapy, and as we all know, about 40% to 50% of patients may not need treatment afterwards. Whether we can say that those patients are potentially cured, maybe. That's why CAR T has more long-term data, more robust data in that setting.
Now, bispecific [therapy is] evolving. We are not seeing that proportion of patients staying in remission that long term. But with further follow-up, we might see that maybe some portion of patients [are] not requiring treatment afterwards. But they're also complementary. What I mean by that [is], if you get CAR T-cell therapy and if you progress, still you can get bispecific, and then you will still respond. There is a good bit of chance of response, and so is the other way around.
If you got bispecific and if you progress, then you can get CAR T and still may have a response. They both target different targets. Bispecific targets CD20 and CAR T-cell targets CD19, so that's a unique difference of, so to speak, an attack on the cancer. So they're kind of complementary to each other.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More